Cost-Reduction Opportunity Target self-funded employers and benefits brokers with Regenexx Corporate Program messaging that highlights potential to reduce orthopedic healthcare costs by up to 70% through non-surgical alternatives to elective surgeries.

Non-Surgical Advantage Position Regenexx as a low-risk, non-surgical option for pain and function improvement that complements existing employee health plans, appealing to employers aiming to minimize surgical interventions.

Employer Adoption Leverage the extensive corporate network (over 2,000 employer groups) to identify large opportunities, channel partnerships, and case studies demonstrating tangible savings and improved employee outcomes.

Clinical Differentiation Emphasize Regenexx’s leadership in stem cell therapy, including bone marrow concentrate processing with high stem cell concentration, to differentiate from competitors in the regenerative medicine market.

Revenue Growth Signals Use the company’s mid-market revenue scale (50M–100M) and solid publication footprint to approach mid-to-large employers and health plans seeking proven, scalable regenerative solutions with measurable ROI.